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O B J E C T I V E S The purpose of this study was to identify the effects of spironolactone on left ventricular
(LV) structure and function, and serological ﬁbrosis markers in patients with metabolic syndrome (MS) taking
angiotensin-converting enzyme inhibitors or angiotensin receptor blockers.
B A C KG ROUND Myocardial ﬁbrosis may be an important contributor to myocardial impairment in
MS, and aldosterone antagonism may reduce ﬁbrosis.
METHOD S Eighty patients (age 59  11 years) with MS, already being treated with angiotensin II
inhibition, were randomized to spironolactone 25 mg/day or placebo for 6 months. Each patient underwent
baseline and follow-up conventional echocardiography and color tissue Doppler imaging. Raw data ﬁles were
used to measure calibrated integrated backscatter and to calculate radial and longitudinal strain. Blood was
obtained at baseline and follow-up to measure ﬁbrosis markers (procollagen type III amino-terminal
propeptide and procollagen type I carboxy-terminal propeptide [PICP]).
R E S U L T S The spironolactone group showed signiﬁcant improvement of LV function, myocardial
reﬂectivity, and LV hypertrophy, with a parallel decrease in levels of PICP and procollagen type III
amino-terminal propeptide. No analogous changes were seen in the placebo group. Baseline strain ( 0.47,
p 0.0001), spironolactone therapy (0.38, p 0.0001), and change in PICP level (0.19, p 0.03)
were independently associated with LV systolic function improvement (increase in strain). Correlates of LV
diastolic function improvement (increase in early diastolic mitral annular velocity) were baseline early diastolic
mitral annular velocity ( 0.47, p 0.0001), spironolactone therapy (0.21, p 0.03), change in PICP
level (  0.23, p  0.02), and age (  0.22, p  0.04). Favorable effects of spironolactone on cardiac
function were not demonstrated in patients with less ﬁbrosis (the lower baseline PICP tertile) or preserved
function (the upper baseline strain tertile).
CONC L U S I O N S Addition of spironolactone to standard angiotensin II inhibition improved
myocardial abnormalities and decreased ﬁbrotic markers in MS. The magnitude of beneﬁt on cardiac
performance is determined mainly by baseline LV dysfunction and collagen turnover as well its response
to intervention. (J Am Coll Cardiol Img 2011;4:1239–49) © 2011 by the American College of Cardiology
Foundation
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1240T
he constellation of cardiovascular risk fac-
tors represented by metabolic syndrome (MS)
is associated with increased cardiovascular
morbidity and mortality. Cardiac complica-
ions of MS include abnormal left ventricular (LV)
tructure and function, leading progressively to
ongestive heart failure (1–5). As the prevalence of
his condition rises to nearly a quarter of the adult
opulation, exceeding 40% in those older than 50
ears (6), these cardiac ramifications are likely to
ecome a major public health concern.
See page 1250
The mechanisms behind cardiac de-
rangements in MS are multifactorial, but
one of the pivotal contributors is thought
to be myocardial fibrosis (7). Accordingly,
measures targeting this pathophysiology
might improve outcomes by reducing the
pathological substrate accounting for myocar-
dial impairment. The renin-angiotensin-
aldosterone (RAA) system has been in-
criminated in the process of cardiac
fibroblast proliferation and collagen syn-
thesis. However, although angiotensin-
converting enzyme inhibitors (ACEIs)
and angiotensin receptor blockers (ARBs)
are widely used for the treatment of hy-
pertension in MS, suboptimal aldosterone
suppression due to “aldosterone escape”
(8–10) may limit the potential suppression
of myocardial fibrosis by these drugs.
Aldosterone antagonists (AAs) may im-
prove LV systolic and diastolic function as
well as reduce cardiac fibrosis in various
heart diseases (11–17), although the com-
bination of AAs and ACEIs/ARBs is less
well explored (18,19). The effect on the
extracellular matrix was a contributor to
the improved outcomes in 2 large random-
ized trials that demonstrated that the addition of
AAs to standard therapy (including ACEIs or
ARBs) diminished the risk of mortality and mor-
bidity in heart failure (20,21). Given the role of
enhanced fibrosis in the pathophysiology of meta-
bolic disorders, as well as growing evidence on the
beneficial effect of AAs extending beyond patients
with moderate to severe heart failure (17,22), we
hypothesized that implementation of spironolac-
tone in addition to drugs opposing angiotensin II
would improve cardiac abnormalities in the popu-
t
ing
ral
e
I
elation with MS regardless of the symptoms of heart sdecompensation. Circulating markers of collagen
type I and type III turnover—procollagen type I
carboxy-terminal propeptide (PICP) and procolla-
gen type III amino-terminal propeptide (PII-
INP)—may reflect the intensity of myocardial fi-
brosis and thus may provide insight into fibrous
tissue accumulation in the heart muscle (23–25). In
this randomized controlled trial, we sought to
determine the effects of adding spironolactone to
ACEIs or ARBs on LV structure and function and
serological fibrosis markers in patients with MS.
M E T H O D S
Study design. The present study was designed as a
rospective, blinded, parallel-group, placebo-
ontrolled trial evaluating the potential of 6 months of
reatment with spironolactone 25 mg/day to improve
ardiac function and morphology and reduce fibrosis
ntensity in patients with MS. The primary endpoints
ere alterations in LV function as assessed by systolic
chocardiographic parameters (strain and peak systolic
train rate [SR]) and diastolic parameters (peak early
iastolic velocity [Em] and the ratio of mitral inflow
arly diastolic velocity to peak early diastolic mitral
nnular velocity [E/e=]). Secondary endpoints in-
luded changes in collagen metabolism as reflected by
erum levels of PICP and PIIINP, myocardial
chodensity as estimated by integrated backscatter
IB), LV wall thicknesses, and LV mass. This report
ollows the recommendations of the 2010 Consoli-
ated Standards of Reporting Trials Statement (26).
Sample size was calculated on the basis of previous
ata from patients with MS (1). Assuming a signifi-
ant difference in peak strain of 10% between spirono-
actone and placebo and applying the variance seen in
ur patients, the predicted sample size was 37 per
roup at 95% power and 2-sided alpha level of 0.05.
o allow for possible dropouts, we increased the
umber of patients in each group to 40.
Randomization to spironolactone or matching pla-
ebo was done in blocks of 10 with an allocation ratio
f 1:1 using sequentially numbered, opaque, sealed
nvelopes. The randomization list and the study drugs
ere prepared by the assigned person coordinating the
tudy, who was not involved in the procedures. Pa-
ients’ selection and randomization were carried out by
he designated investigators. The study participants
nd the investigators assessing the outcomes were
linded to group assignment.
Study medication was withheld in the presence ofA B B R E V I A T I O N S
A N D A C R O N YM S
A peak late diastolic flow
velocity
AA aldosterone antagonis
ACEI angiotensin-convert
enzyme inhibitor
ARB angiotensin receptor
blocker
E peak early diastolic flow
velocity
e= peak early diastolic mit
annular velocity
Em peak early diastolic
myocardial velocity
IB integrated backscatter
LV left ventricular
MSmetabolic syndrome
PICP procollagen type I
carboxy-terminal propeptid
PIIINP procollagen type II
amino-terminal propeptide
RAA renin-angiotensin-
aldosterone
SR peak systolic strain rat
TGF transforming growthignificant hyperkalemia (5.5 mmol/l), renal impair-
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1241ment (serum creatinine310 mol/l [3.5 mg/dl]), or
erious side effects.
Patient selection. We screened 132 patients with
cardiovascular risk factors (hypertension, diabetes
mellitus, and obesity) who were referred to special-
ist clinics for management of MS and recruited 80
consecutive patients satisfying the selection criteria
(Fig. 1). The diagnosis of MS was established as
recommended by the amended National Choles-
terol Education Program’s Adult Treatment Panel
III guidelines in patients meeting 3 of the follow-
ing criteria: 1) increased waist circumference (102
cm in men or 88 cm in women); 2) increased
fasting triglycerides (1.7 mmol/l) or drug treat-
ment for elevated triglycerides; 3) high blood pres-
sure (130/85 mm Hg) or antihypertensive ther-
apy; 4) decreased high-density lipoprotein
cholesterol (1.03 mmol/l in men or 1.3 mmol/l
in women) or drug treatment for reduced high-
density lipoprotein cholesterol; 5) impaired fasting
glucose (5.6 mmol/l) or drug treatment for ele-
vated glucose (27). To be eligible, patients had to
remain on stable pharmacotherapy including
ACEIs or ARBs for6 months before entering the
study.
Coronary artery disease was excluded on the basis
of a negative history and normal stress echocardio-
gram. Other exclusion criteria included moderate
and severe valvular heart disease; absence of stable
sinus rhythm; adrenocortical disorders; pulmonary,
hepatic, rheumatic, neoplastic, skeletal, thyroid, and
renal diseases (including renal insufficiency with
serum creatinine 220 mol/l [2.5 mg/dl]), hyper-
alemia 5.0 mmol/l; and treatment with AAs.
Figure 1. Study Flow DiagramAll participants were informed of the purpose of
he study and provided written informed consent.
nvestigations were in accordance with the Decla-
ation of Helsinki and were approved by the insti-
utional ethics committee.
Study protocol. At baseline, enrolled patients un-
erwent physical examination (with blood pressure
easurement), blood specimen collection, and
chocardiography. Thereafter, patients were ran-
omized to receive either 25 mg of spironolactone
r placebo once daily. Previous pharmacotherapy
as maintained unchanged. Patients’ status, com-
liance with the treatment, and serum electrolyte
evels were monitored at visits every 2 weeks during
he first 2 months and then monthly. The baseline
nvestigations were repeated after 6 months.
Blood assays. Peripheral venous blood was obtained
etween 8:00 AM and 9:00 AM after 30 min of rest.
erum PICP level was measured with an enzyme-
inked immunoadsorbent assay (Takara Bio, Shiga,
apan); intra-assay and interassay coefficients of
ariation (CVs) were 4.9% and 5.5%, respectively.
erum PIIINP level was quantified by radioimmu-
oassay (Orion Diagnostica, Espoo, Finland);
ntra-assay and interassay CVs were 3.9% and 5.3%,
espectively. Serum level of transforming growth
actor (TGF)-1 was estimated using an enzyme-
linked immunoadsorbent assay (R&D Systems,
Minneapolis, Minnesota); intra-assay and interas-
say CVs were 2.7% and 7.0%, respectively. Serum
aldosterone level was assessed by radioimmunoassay
(Immunotech SAS, Marseille, France); intra-assay
and interassay CVs were 7.6% and 8.8%, respec-
tively. Plasma angiotensin II levels were quantified
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1242by radioimmunoassay (DIAsource ImmunoAssays,
Nivelles, Belgium); intra-assay and interassay CVs
were 3.1% and 4.3%, respectively.
Echocardiography. Imaging was performed using
tandard equipment (Vivid 7 and System 5, GE
ltrasound, Horten, Norway) with phased-array
.5-MHz multifrequency transducers.
CONVENTIONAL ECHOCARDIOGRAPHY. Cardiac di-
ensions and wall thickness were measured according to
tandard recommendations (28). LV mass was derived
rom the modified American Society of Echocardiogra-
hy cube formula and indexed for height to the power of
.7 (29). LV ejection fraction was assessed by a modified
impson biplane method.
Pulsed-wave Doppler recordings of the LV in-
ow were obtained from the apical 4-chamber view
ith the sample volume placed between the tips of
he mitral leaflets. E and late diastolic flow velocity
A) (E/A) and deceleration time of early diastolic
ow wave were estimated.
CALIBRATED IB. IB is a marker of myocardial re-
flectivity that has previously been correlated with
histological evidence of fibrosis (30). IB curves were
obtained from a 9  9-pixel sample volume in
end-diastole in the basal anteroseptum, posterior
wall, and pericardium in the parasternal long-axis
view. Calibrated IB was calculated by subtracting
average pericardial IB from average myocardial IB
intensity in 3 consecutive cardiac cycles.
PULSED-WAVE TISSUE DOPPLER. Recordings of the
eptal and lateral portion of annulus were used for
he assessment of e=. E/e= obtained from the septal
nd lateral sides of the mitral annulus was calculated
o approximate LV filling pressure.
MYOCARDIAL DEFORMATION. Color tissue Doppler
myocardial imaging data were acquired in the 3 apical
views to evaluate LV longitudinal function and in the
parasternal short-axis view to quantify LV radial
performance. The narrowest possible image sector and
the optimal depth of imaging were applied to achieve
maximal frame rate. Pulse repetition frequency was set
at the lowest value without aliasing. The ultrasound
beam was kept as parallel as possible to the myocardial
segment of interest to ensure an insonation angle
20°. The sampling window was placed in the central
part of each segment and maintained at the same
position by manually tracking the wall motion during
the cardiac cycle.
Digital data were analyzed offline (Echopac, GE
Medical). Regional myocardial velocity curves were
extracted from color Doppler data obtained in the bbasal segment of the interventricular septum to
estimate peak systolic velocity and Em. LV longi-
tudinal myocardial deformation was assessed in the
apical, mid, and basal segments of each wall,
whereas LV radial myocardial deformation was
assessed in the basal posterior segment. SR was
evaluated from the spatial velocity gradient over a
12-mm computation length in the longitudinal di-
rection and 1 mm less than the end-diastolic wall
thickness in the radial direction. SR profiles were then
integrated over time to obtain strain curves triggered
to the R-peak of the electrocardiogram. Parameters
estimated from myocardial deformation curves in-
cluded peak strain, defined as the greatest negative
value on the strain curve, and SR. All strain, SR, and
myocardial velocity profiles were averaged from 3
consecutive cardiac cycles. The results for strain and
SR are presented as the average values from all
segments subjected to analysis.
REPRODUCIBILITY. The reproducibility of myocar-
dial measurements was calculated using values
averaged from all of the segments assessed in 15
randomly selected examinations. The intraob-
server and interobserver variability was 0.7 
0.4% and 0.8  0.5% for strain, 0.05  0.02 s1
and 0.07  0.04 s1 for strain rate, 0.2  0.3
cm/s and 0.3  0.3 cm/s for myocardial veloci-
ties, and 1.2  1.3 dB and 1.4  1.4 dB for
calibrated IB, respectively.
The evaluation of baseline collagen metabolism in
patients with MS was based on a comparison with serum
levels of PICP and PIIINP obtained from 34 healthy
volunteers of comparable age (57.1  8.5 years) with
normal cardiac function and morphology.
Statistical analysis. Data are presented as mean 
D; skewed variables (C-reactive protein, serum
ldosterone) were log-transformed. Between-group
omparisons were performed with an unpaired
-sided Student t test or, when more than 2 groups
ere included, by 1-way analysis of variance with
he Scheffe post hoc test for continuous variables
nd chi-square test for categorical variables. Homo-
eneity of variances was evaluated by the Levene
est. Longitudinal analyses were carried out using a
epeated-measures 2-way analysis of variance with
lanned comparisons by the linear contrasts
ethod. Associations between variables were ex-
ressed with Pearson or Spearman correlation co-
fficients and stepwise multiple regression analysis.
ffect size was evaluated using the Cohen d
ethod. Changes in particular parameters with
ntervention were calculated by subtracting the
aseline value from the follow-up value. All analy-
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1243ses were performed with standard statistical soft-
ware (Statistica for Windows 8, StatSoft Inc.,
Tulsa, Oklahoma). The level of statistical signifi-
cance was set at p  0.05.
R E S U L T S
Patient characteristics. The baseline characteristics
of the spironolactone and placebo groups (demo-
graphics and clinical and laboratory parameters) are
summarized in Tables 1 and 2. Three components
of MS were present in 38% of the treatment group
and in 36% of the placebo group, with 4 compo-
nents in 33% and 38% and 5 components in 30%
and 26%, respectively. All of the randomized pa-
tients were asymptomatic or had minor limitation
of physical activity (New York Heart Association
functional class I to II). Comparisons with healthy
controls revealed increased levels of the fibrosis
markers in patients with MS—PICP (117.9 41.2
g/l in the referent group, p  0.01 vs. spironolac-
tone and p  0.002 vs. placebo group) and PIIINP
(4.39  0.96 g/l in controls, p  0.002 vs.
pironolactone and p  0.03 vs. placebo group).
Adherence and drug side effects. One patient in the
lacebo group did not complete the study proto-
ol because of changing residence. Mild gyneco-
Table 1. Demographic Data, Baseline and Follow-Up Values, an
Spirono
Baseline
Clinical features
Age, yrs 58.4 11.5
Male 19 (48)
Diabetes mellitus 23 (58)
BMI, kg/m2 32.8 4.8
Waist circumference, cm 101 11
Waist/hip ratio 0.97 0.14
Systolic blood pressure, mm Hg 143 16
Diastolic blood pressure, mm Hg 82 9
Medications
ACEI 35 (88)
ARB 5 (13)
Beta-adrenolitics 24 (60)
Calcium antagonist 13 (33)
Diuretic (hydrochlorothiazide or indapamide) 19 (48)
Statin 27 (68)
Fibrate 3 (8)
Sulfonylurea 11 (28)
Biguanide 13 (33)
Values are mean  SD or n (%).
ACEI  angiotensin-converting enzyme inhibitor; ARB  angiotensin recepto
∆Placebo  change in the placebo group during follow-up.astia developed in 2 male patients in the spi-
onolactone group but did not lead to drug
iscontinuation. No other adverse effects or com-
lications occurred.
Baseline echocardiography. No differences between
the treatment and placebo groups in all of the
baseline echocardiographic indexes of cardiac struc-
ture and function were demonstrated (Table 3).
Patients with MS presented LV structural and
functional abnormalities as compared with healthy
referents: increased LV end-diastolic dimension,
LV mass index, left atrial dimension, E/e= and IB in
the basal anteroseptum, and decreased Em, longi-
tudinal strain, and longitudinal SR (the values in
the control group were 46.7  3.0 mm for LV
end-diastolic dimension, 41.0  5.8 g/m2.7 for LV
ass index, 36.0  2.7 mm for left atrial dimen-
ion, 8.9  1.5 for E/e=, 20.6  5.3 dB for the
asal septal IB, 8.3  2.6 cm/s for Em, 20.4 
.3% for longitudinal strain, and 1.61  0.18 s1
for SR; all p  0.001 vs. the MS groups).
Clinical and laboratory parameters. No significant
changes were noted from baseline to 6 months in
either group in parameters related to adipose tissue
content, blood pressure, plasma lipid level, C-reactive
protein level, renal function and metabolic control
ange During Follow-Up of Clinical Characteristics
tone (n  40) Placebo (n  39)
llow-Up p Value Baseline Follow-Up p Value
— — 60.6 11.4 — —
17 (44)
21 (54)
.4 4.7 0.37 31.6 4.0 31.3 4.1 0.28
0 11 0.26 99 10 99 10 0.39
6 0.13 0.30 0.96 0.10 0.96 0.10 0.50
0 14 0.21 139 12 137 11 0.32
0 6 0.23 82 6 80 6 0.22
32 (82)
7 (18)
20 (51)
10 (26)
21 (54)
22 (56)
3 (8)
9 (23)
10 (26)
cker; BMI  body mass index; ∆Spironolactone  change in the spironolactoned Ch
lac p Value
Fo
Spironolactone
vs. Placebo
32 0.69
10 0.24
0.9 0.28
14 0.67
8 0.82
r blo group during follow-up;
t
w
abbreviations as in Figur
TGF  transforming grow
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1244parameters, blood aldosterone level, and angioten-
sin II level. There was a mild increase in serum
potassium in the spironolactone group but no sig-
nificant change with placebo (Tables 1 and 2).
low-Up Values, and Change During Follow-Up of Echocardiograp
Spironolactone (n  40)
Baseline Follow-Up p Value
sion, mm 51.8 4.2 52.0 4.1 0.41
13.4 1.9 12.8 1.7 0.001
10.5 1.4 10.1 1.5 0.02
62.3 10.1 59.6 10.9 0.003
m 44.0 3.2 42.9 3.3 0.001
67.6 3.9 67.9 4.1 0.52
12.4 2.9 11.6 3.2 0.01
0.95 0.19 0.95 0.21 0.93
239 43 238 44 0.91
5.6 1.4 5.8 1.2 0.08
5.7 1.5 6.3 1.4 0.03
17.5 2.7 19.2 2.3 0.001
1.41 0.25 1.55 0.20 0.001
41.4 14.0 39.6 10.4 0.58
2.87 0.92 2.77 0.70 0.55
13.6 5.0 14.4 4.2 0.37 
25.3 5.0 27.6 5.2 0.04 
of early diastolic ﬂow wave; E/A  ratio of peak early and late diastolic ﬂow ve
 peak early diastolic velocity; IB AS  calibrated integrated backscatter in
erventricular septal thickness; LV  left ventricular; PW  LV posterior wal
low-Up Values, and Change During Follow-Up of Laboratory Cha
Spironolactone (n  40)
Baseline Follow-Up p Value
13.3 9.5 13.6 9.7 0.88
l 123 33 119 31 0.36
4.1 3.0 4.1 3.7 0.87
0.93 0.21 0.90 0.23 0.27
6.7 1.7 6.8 1.5 0.82
4.2 0.3 4.5 0.3 0.001
l 200 43 194 36 0.38
n, mg/dl 121 39 113 40 0.36
in, mg/dl 49 13 49 13 0.64
167 78 157 76 0.28
/l 3.5 2.7 4.3 4.3 0.30
5.76 1.99 4.91 1.73 0.003
142.1 33.2 122.1 23.1 0.001
33.8 7.1 30.7 6.0 0.01
80.5 64.4 92.6 77.1 0.22
11.7 4.7 12.7 6.6 0.40
less otherwise indicated.
model assessment of insulin resistance; PICP  procollagen type I carboxy-term
th factor; other abbreviations as in Table 1.e 1.Circulating levels of the fibrotic markers PICP,
PIIINP, and TGF-1 significantly decreased in the
reatment group. No analogous changes were found
ith placebo (Table 2).
Characteristics
Placebo (n  39) p Value
seline Follow-Up p Value
Spironolactone
vs. Placebo
.1 4.2 50.7 4.0 0.30 0.14
.2 1.7 13.1 1.7 0.49 0.04
.1 1.3 10.0 1.3 0.38 0.30
.4 11.5 59.0 12.2 0.35 0.47
.8 4.2 42.7 4.7 0.77 0.01
.1 4.6 67.3 4.3 0.66 0.64
.4 2.7 11.5 2.4 0.52 0.01
3 0.42 0.92 0.31 0.67 0.77
8 43 230 37 0.21 0.30
.8 1.3 5.8 1.3 0.95 0.13
.9 1.6 5.8 1.7 0.47 0.005
.9 2.6 17.8 2.6 0.52 0.001
3 0.21 1.43 0.22 0.55 0.001
.6 13.1 40.3 13.6 0.37 0.28
4 0.71 2.87 0.72 0.33 0.36
.1 5.3 15.0 4.4 0.80 0.45
.1 5.7 24.1 4.4 0.25 0.30
ties; E/e=  ratio of peak early mitral inﬂow velocity and peak early diastolic
asal anteroseptum; IB post  calibrated integrated backscatter in the basal
kness; Sm  peak systolic velocity; SR  peak systolic strain rate; other
eristics
Placebo (n  39) p Value
seline Follow-Up p Value
Spironolactone
vs. Placebo
.8 9.8 11.1 8.7 0.35 0.45
8 31 113 19 0.23 0.81
.1 4.1 3.1 2.7 0.29 0.29
3 0.21 0.93 0.25 0.82 0.41
.3 1.3 6.3 1.0 0.86 0.97
.1 0.3 4.2 0.3 0.56 0.01
8 41 194 32 0.41 0.68
6 32 115 32 0.91 0.36
2 15 50 13 0.36 0.19
8 57 151 46 0.24 0.75
.1 2.9 3.6 2.6 0.26 0.59
2 1.92 5.20 1.96 0.50 0.02
.1 43.6 145.9 47.4 0.38 0.02
.9 7.0 31.6 6.4 0.57 0.02
.2 54.6 63.2 45.2 0.77 0.09
.9 7.4 11.8 6.4 0.64 0.13
ropeptide; PIIINP  procollagen type III amino-terminal propeptide;Table 3. Baseline, Fol hic
Ba
LV end-diastolic dimen 51
IVS, mm 13
PW, mm 10
LV mass index, g/m2.7 60
Left atrial dimension, m 42
LV ejection fraction, % 67
E/e= 11
E/A 0.9
DT, ms 23
Sm, cm/s 5
Em, cm/s 5
Longitudinal strain, % 17
Longitudinal SR, s1 1.4
Radial strain, % 39
Radial SR, s1 2.8
IB AS, dB 15
IB post, dB 23
Values are mean  SD.
DT  deceleration time loci
mitral annular velocity; Em the b
posterior wall; IVS  int l thicTable 2. Baseline, Fol ract
Ba
Fasting insulin, mIU/l 12
Fasting glucose, mg/d 11
HOMA-IR 4
Creatinine, mg/dl 0.9
Uric acid, mg/dl 6
Potassium, mmol/l 4
Total cholesterol, mg/d 19
Low-density lipoprotei 11
High-density lipoprote 5
Triglycerides, mg/dl 15
C-reactive protein, mg 3
PIIINP, g/l 5.3
PICP, g/l 150
TGF-1, g/ml 31
Aldosterone, pg/ml 68
Angiotensin II, pmol/l 13
Values are mean  SD, un
HOMA-IR  homeostasis inal p
s
d
i
E
m
i
i
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1245Echocardiographic parameters of cardiac function and
morphology. The spironolactone group demon-
strated a significant decrease in LV mass index,
interventricular septal thickness, LV posterior wall
thickness, and left atrial diameter at follow-up (Table 3).
The improvement in LV systolic function in the
spironolactone group was evidenced by increase in
longitudinal strain and SR, whereas that in LV
diastolic function was characterized by increase in
Em and decrease in E/e= (Table 3). The improve-
ment in myocardial tissue density with spironolac-
tone therapy was reflected by a decrease in cali-
brated IB in the basal posterior wall (Table 3).
All echocardiographic parameters of cardiac
function and morphology remained unchanged over
the intervention period in the placebo group.
Response to spironolactone therapyaccording tobaseline
PICP tertiles. Significant differences in changes in
strain, SR, and Em between the spironolactone and
placebo groups, reflecting LV function improvement
with intervention, were seen in the middle and upper
but not in the lower baseline PICP tertile. The effect
size was medium in the first tertile and large in the
second and third tertiles for all 3 variables. Changes in
strain, SR, and Em in the treatment group were lower
in the first PICP tertile than in the second and third
Figure 2. Left Ventricular Function Response to Spironolactone
The range of procollagen type I carboxy-terminal propeptide (PICP)
second tertile, and 170.0 to 215.7 g/l in the third tertile. ∆Em  c
change in longitudinal peak systolic strain rate with intervention; ∆StraPICP tertiles. No differences in this regard were
shown in the placebo group (Fig. 2).
Response to spironolactone therapy according to base-
line longitudinal strain tertiles. Significant differences
in changes in PICP and PIIINP levels between the
spironolactone and placebo groups were revealed in
the first baseline longitudinal strain tertile, whereas
those of LV function parameters (i.e., longitudinal
strain, SR, and Em) were seen in the first and
second tertiles. The effect was found to be large in
the first and second tertiles and small in the third
tertile for cardiac functional indexes and large in the
first tertile and small in the second and third tertiles
for the procollagen peptides. Changes in LV lon-
gitudinal deformation parameters in the spironolac-
tone group were higher in the lower and middle
than in the upper strain tertile. The placebo group
demonstrated no differences in this respect (Fig. 3).
Relation of changes in cardiac and ﬁbrosis markers. A
eries of models was developed to identify the indepen-
ent associations of LV systolic and diastolic function
mprovement (as indicated by increase in strain, SR, and
m and decrease in E/e=). The components of these
odels, selected on the basis of anticipated association
ncluded age, sex, blood pressure, baseline body mass
ndex, homeostasis model assessment of insulin resis-
rapy Across Baseline PICP Tertiles
s 58.5 to 129.5 g/l in the ﬁrst tertile, 133.1 to 169.3 g/l in the
ge in peak early diastolic velocity with intervention; ∆SR The
wa
hanin  change in longitudinal strain with intervention.
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1246tance, markers of fibrosis (baseline values and follow-up
changes of PICP and PIIINP levels), myocardial
echodensity (baseline values and follow-up changes
of IB in the basal posterior wall), baseline LV
performance, and treatment with spironolactone.
The independent determinants (Table 4) were
baseline LV performance, baseline PICP level and
its change at follow-up, treatment with spironolac-
tone, change in calibrated IB in the basal posterior
-1
p<0.001
1st Strain tertile∆Strain
Spironolactone 2.71±1.57 1.93±1.18 -0.56±1.20
Placebo 0.45±0.75 -0.09±0.68 -0.51±1.34
P 0.001 0.001 0.92
d 1.84 2.10 0.05
0.5
1
-0.5
1.5
2
2.5
3
2nd Strain tertile 3rd Strain tertile
1st Strain tertile 2nd 
0
∆ Strain
%
-0.4
∆Em
Spironolactone 0.91±1.12 0
Placebo -0.11±0.91 -0
P 0.02 
d 1.00 
0.2
-0.2
0.4
0.6
0.8
1
1.2∆ Em
cm
/s
0
-30
p=0.19
1st Strain tertile∆PICP
Spironolactone -26.9±37.6 -21.2±37.4 -8.2±25.3
Placebo 0.9±24.6 -16.5±23.2 -1.4±22.1
P 0.04 0.63 0.32
d 0.88 0.15 0.29
-20
-15
-25
-10
-5
5
2nd Strain tertile 3rd Strain tertile
0
∆ PICP
µg
/L
Spiro
Place
A
B
Figure 3. Left Ventricular Function (A) and Propeptide (B) Resp
Tertiles
The range of strain was 13.5% to 16.7% in the ﬁrst tertile, 16.8% to
The greatest change of systolic and diastolic function were in the s
type I carboxy-terminal propeptide level with intervention; ∆PIIIINP
with intervention; other abbreviations as in Figure 2.wall at follow-up, and patient age.A model was also developed to identify the inde-
pendent associations of myocardial density, a marker
of fibrosis (as reflected by decrease in calibrated IB in
the basal posterior wall). After adjustment for poten-
tial associations (including age, sex, treatment group,
homeostasis model assessment of insulin resistance,
blood pressure, and baseline and follow-up alterations
in PICP level, PIIINP level, and LV mass index), the
only independent correlate was a change in PICP
 tertile 3rd Strain tertile
1st Strain tertile 2nd Strain tertile 3rd Strain tertile
.14
0.86 0.13±1.34
1.06 0.10±0.72
2 0.90
0 0.03
-0.05
p<0.001
1/
s
∆SR
Spironolactone 0.22±0.13 0.15±0.11 -0.02±0.12
Placebo 0.04±0.04 -0.02±0.04 -0.03±0.10
P 0.001 0.001 0.89
d 1.87 2.05 0.10
0.05
0.1
0.15
0.25
0.2
0
∆ SR
Spironolactone
Placebo
-1.5
1st Strain tertile 2nd Strain tertile 3rd Strain tertile
-2
p=0.28
m
g/
L
∆PIIINP
Spironolactone -1.63±1.62 -0.47±1.81 -0.38±1.34
Placebo -0.22±1.07 -0.08±1.03 -0.09±1.31
P 0.02 0.46 0.58
d 1.03 0.27 0.22
-1
-0.5
1
0.5
 PIIINP
tone
0
to Spironolactone Therapy Across Baseline Longitudinal Strain
8% in the second tertile, and 18.9% to 21.7% in the third tertile.
ents with worst baseline function. ∆PICP  change in procollagen
hange in procollagen type III amino-terminal propeptide levelStrain
p=0
.50±
.37±
0.0
0.9
∆
nolac
bo
onse
18.
egm
 c(  0.25, p  0.02).
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1247Moreover, significant univariate correlations be-
tween spironolactone therapy and changes in the
levels of the procollagen peptide—PICP and PIIINP
were demonstrated (both r  0.22, p  0.05).
D I S C U S S I O N
This randomized placebo-controlled study demon-
strated that the addition of spironolactone to standard
treatment including ACEIs or ARBs for 6 months
improved myocardial abnormalities, with a concurrent
decrease in fibrotic markers in patients with MS. The
magnitude of benefit on cardiac performance was
determined mainly by the degree of baseline LV
dysfunction and the extent of collagen turnover at
baseline as well as its response to intervention.
Potential mechanisms. Cardiac morphofunctional de-
rangements in MS are due to a complex interplay of
the multiple components of this disease condition.
The mechanisms responsible for cardiac pathologies
in MS include increased myocardial fibrosis, inflam-
mation, oxidative stress, hyperinsulinemia and insulin
resistance (causing abnormal myocardial substrate
use), intracellular lipid accumulation and lipotoxicity
(causing cardiomyocyte apoptosis), neurohormonal
activation (especially the RAA and sympathetic sys-
tems), endothelial dysfunction, disturbances of adipo-
kine release and signaling, and altered ventricular load
(2,4,5,7,31). Of these, RAA system upregulation is an
important part of the pathophysiological process that
Table 4. Multivariable Predictors of LV Function Improvement
 p Value
∆Strain (R2  0.52)
Baseline strain 0.47 0.0001
Spironolactone treatment 0.38 0.0001
∆PICP 0.19 0.03
∆SR (R2  0.56)
Baseline SR 0.52 0.0001
Spironolactone treatment 0.52 0.0001
Baseline PICP 0.16 0.04
BMI 30 kg/m2 0.12 0.11
∆Em (R2  0.32)
Baseline Em 0.47 0.0001
∆PICP 0.23 0.02
Spironolactone treatment 0.21 0.03
Age 0.22 0.04
∆E/e= (R2  0.22)
Baseline E/e= 0.30 0.006
Spironolactone treatment 0.22 0.04
∆IB post 0.21 0.04
Baseline PICP 0.19 0.07
∆ indicates change with intervention.
Abbreviations as in Tables 1 and 3.promotes free radical formation and cell proliferation tand exerts proinflammatory and profibrotic effects
(32). Both angiotensin II and aldosterone participate
in extracellular matrix remodeling by enhancing col-
lagen synthesis: angiotensin II via TGF-1 and aldo-
sterone stimulation and aldosterone directly and
through TGF-1 (33,34). These observations provide
he rationale for aldosterone antagonism to reduce
yocardial fibrosis.
The present study supports the favorable cardiac
ffect of aldosterone antagonism in MS by revealing
n incremental benefit to angiotensin II inhibition.
he 6-month follow-up duration in the current study
as established in accordance with the fibrillar colla-
en half-life to be long enough to allow for the
limination of a considerable amount of collagen from
he myocardium and hence the identification of the
ffects of treatment. The amelioration of LV function
nd structure abnormalities was paralleled by a de-
rease in the levels of serological markers of fibrosis
PICP and PIIINP) and the fibrotic mediator TGF-
1. The independent association of PICP with signif-
cant LV systolic and diastolic function improvement
upports the concept that inhibition of myocardial
brosis with intervention might have contributed to
unctional recovery. Likewise, independent associa-
ions between the favorable changes in PICP level and
n index of ultrasonic tissue characterization directly
elated to the morphometrically assessed myocardial
ollagen volume fraction (calibrated IB) as well as
etween the latter and diastolic improvement (E/e=)
re consistent with the antifibrotic properties of spi-
onolactone. The observation that the beneficial ef-
ects of aldosterone antagonism were more pro-
ounced in patients with greater initial intensity of
ollagen anabolism is in line with previous findings in
ther disease populations (17).
Collagen markers. Our investigations suggest that
PICP is superior to PIIINP in predicting changes of
LV function and echodensity. This is not an unex-
pected finding because collagen type I represents more
than 80% of total cardiac collagen and is the major
component of myocardial extracellular matrix (35).
The moderate improvement of LV function with
spironolactone in this study was less than that reported
previously in a hypertensive cohort (15), which might
be attributable to a lesser intensity of fibrosis in this
setting or the widespread use of ACEIs/ARBs limit-
ing the baseline extent of fibrosis. The observed
decrease in TGF-1 level associated with spironolac-
one antagonism, concordant with experimental evi-
ence (11,12), was not independently associated with
he demonstrated improvement in LV abnormalities.
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1248Study limitations. In this study, echocardiographic
markers of cardiac function were used as physiological
endpoints. The association of these endpoints with
clinical manifestations of heart failure and events has
been shown in a number of previous investigations.
Whether use of AAs in MS over a longer time span
could improve outcome is a crucial question that needs
to be verified in subsequent studies.
The characterization of fibrosis remains chal-
lenging. The imaging tests for this process are
imperfect—we used tissue Doppler–based strain in
this and our previous work on obesity because the
signal/noise ratio of Doppler is less susceptible to
imaging problems posed by obesity than are speckle-
tracking–based approaches; however, the direction
sensitivity of Doppler is an acknowledged limita-
tion. Calibrated IB, although previously docu-
mented to correlate with myocardial collagen con-
tent, requires further validation to be considered as
a reliable index of cardiac fibrosis. Similarly, bio-
chemical tests may not be cardiac specific and are
less markers of collagen synthesis than collagen
turnover. This is less the case for circulating PICP,
with a cardiac origin that has been shown in humans
and which is completely cleaved during the conversion
of procollagen type I into collagen type I. It is an
important consideration for PIIINP, the cardiac ori-
gin of which remains to be proven, and PIIINP is not
completely cleaved during the conversion of procolla-
gen type III into collagen type III. Consequently,
PIIINP remains in the collagen fibers and may also be
released during fiber degradation.
Our results suggest a blood pressure–independent
effect of spironolactone, supported by the absence of
changes in blood pressure with intervention as well
as the lack of contribution from blood pressure to
multivariable models of improved cardiac function.
However, these observations are based on clinicHeart J 2007;28:553–9. poulou A, et al. Thpressure monitoring would offer a more compre-
hensive method of studying this association.
The present investigations did not shed light on
the mechanisms underlying the regression of LV
hypertrophy with spironolactone therapy, showing
no associations between the reduction in LV mass
and wall thicknesses with intervention and the
evaluated laboratory and clinical factors. Consider-
ing the importance of the problem, the influence of
aldosterone antagonism on cardiac morphologic
abnormalities merits further exploration.
C O N C L U S I O N S
The addition of an AA to an ACEI or ARB
improves cardiac functional and structural distur-
bances in patients with MS. The mechanisms
contributing to this salutary effect appear consistent
with a limitation of excessive collagen synthesis. In
patients complying with prespecified selection cri-
teria, our investigations confirmed previous obser-
vations that the dose of spironolactone 25 mg/day
in conjunction with drugs antagonizing the action
of angiotensin II was safe and well tolerated. Post
hoc analyses based on tertiles of PICP and longi-
tudinal strain suggest that the favorable effects of
spironolactone may not be evident in patients with
MS with the lowest fibrosis intensity as well as in
those with less profound LV function abnormali-
ties. Conversely, larger benefits gained from spi-
ronolactone therapy were associated with more
severe baseline LV dysfunction and myocardial
fibrosis (evidenced by PICP) and younger patient
age (for diastolic impairment). These observations
may guide the selection of patients with MS who
would most benefit from treatment, but this issue
needs to be addressed in separate, dedicated studies.
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